Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 10/20 | 0.53 |
| ▸ | MC1R | Q01726 | 10/20 | 0.53 |
| ▸ | MC5R | P33032 | 9/20 | 0.53 |
| ▸ | MC3R | P41968 | 9/20 | 0.53 |
| ▸ | CTSG | P08311 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
| ▸ | ITGAV | P06756 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | GRB2 | P62993 | 2/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13649555 | 0.95 | MC4R (0.56) | MC4RMC1RMC5RMC3RCTSG | |
| SCHEMBL13649564 | 0.94 | MC4R (0.55) | MC4RMC1RMC5RMC3RCTSG | |
| SCHEMBL11929552 | 0.89 | ITGB3 (0.57) | MC4RMC1RMC5RMC3RCTSG | |
| SCHEMBL13703200 | 0.89 | MC4R (0.52) | MC4RMC1RMC5RMC3RCTSG | |
| SCHEMBL11929915 | 0.85 | MC4R (0.58) | MC4RMC1RMC5RMC3RCTSG | |
| SCHEMBL13703202 | 0.85 | MC4R (0.52) | MC4RMC1RMC5RMC3RCTSG | |
| SCHEMBL13656508 | 0.83 | MC4R (0.51) | MC4RMC1RMC5RMC3RCTSG | |
| SCHEMBL13703447 | 0.82 | MDM2 (0.44) | MC4RMC1RMC5RMC3RCTSG | |
| SCHEMBL11929553 | 0.81 | MC4R (0.46) | MC4RMC1RMC5RMC3RITGB3 | |
| SCHEMBL16349774 | 0.79 | MC4R (0.51) | MC4RMC1RMC5RMC3RCTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608243-B2 | RGD peptide sequence; labelled with fluorescein used as contrast agents in optical imaging in diagnosis of angiogenesis-related diseases; peptidic vector and the fluorescein dye are coupled; cyclic peptide forming disulife or monothioether bridge | GE HEALTHCARE AS (NO) | 2009-10-27 | — | — | US | disclosed |
| US-20090232741-A1 | Optical Imaging | GE HEALTHCARE AS (NO) | 2009-09-17 | — | — | US | disclosed |
| US-20070183977-A1 | Fluorescein-labelled peptides | AMERSHAM HEALTH AS (NO) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070183977-A1 | Fluorescein-labelled peptides | FLT4, FLT1, KDR | MC4R 379/4885MC1R 124/4885MC5R 676/4885 |
| US-20090232741-A1 | Optical Imaging | AGER, KDR, FLT4 | MC4R 244/4885MC1R 25/4885MC5R 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.